Cardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease

This interview is disseminated on behalf of Cardiol Therapeutics Inc.

In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis.

Learn more: https://www.cardiolrx.com

00:00 Introduction
01:02 The Origins of Cardiol Therapeutics
02:10 Why Inflammation-Driven Heart Disease Matters
03:38 Targeting Recurrent Pericarditis: Cardiol’s Approach
06:28 NDA Pathway, Regulatory Strategy & Key Milestones
08:52 Clinical Data, Trial Progress & Treatment Potential
12:00 The MAVERIC Trial, Capital Position & Growth Catalysts
13:33 Final Thoughts & What Investors Should Watch Next

➡️ Check out https://StockTA.com for FREE Stock Technical Analysis and Trading Tools to make smarter investment decisions.

FOLLOW STOCKS TO WATCH ON:
X: https://x.com/stocks2watch_
TikTok: https://www.tiktok.com/@globalonemedia
Spotify: https://open.spotify.com/show/6VzOJFG6lv85shwRyVEhf7?si=0a3313957c5b455a&nd=1&dlsi=6ef16de1ed434de2


DISCLAIMER: The content presented on Stocks To Watch is for informational and educational purposes only and should not be construed as financial, investment, legal, tax, or other professional advice. Nothing in this video or its accompanying materials constitutes a recommendation, endorsement, solicitation, or offer to buy or sell any securities or to pursue any investment strategy. Viewer discretion is advised, as investments discussed on this channel — particularly in early-stage, junior, exploration, or emerging sectors — carry a high degree of risk and may result in the loss of your entire investment. You should never invest money you cannot afford to lose and are strongly encouraged to conduct your own independent research and consult with a licensed financial professional before making any investment decisions.

Stocks To Watch is operated by Global One Media Group Pte. Ltd. (https://globalonemedia.com), and Global One Media and/or its hosts may receive compensation from the company featured in this video in connection with media creation, corporate communications, digital distribution, and investor awareness efforts. Such compensation may be paid in cash or in securities, including shares, options, or warrants. All interviews on Stocks To Watch are unscripted. The views and statements expressed belong solely to the individuals appearing in the video and do not necessarily reflect the views of Stocks To Watch or Global One Media. Participants speak based on their own knowledge, interpretation, and experience. Global One Media, its directors, employees, representatives, contractors, and guests may hold, buy, or sell securities of companies featured on Stocks To Watch at any time. They are under no obligation to disclose or update their positions, and viewers should assume that Global One Media and its affiliates may have a financial interest in companies discussed.

While reasonable efforts are made to ensure that information shared on Stocks To Watch is accurate and current, no guarantee is made regarding its completeness, reliability, or suitability. Content may include forward-looking statements that involve assumptions, risks, and uncertainties that could cause actual results to differ materially. Stocks To Watch and Global One Media are not registered as securities broker-dealers, investment advisers, or accountants in any jurisdiction and do not provide personalized investment recommendations, suitability assessments, or financial planning services. By continuing to watch this video, you acknowledge and accept that Global One Media operates under the laws of Singapore and that you are responsible for complying with the laws of your own jurisdiction. Global One Media disclaims all liability for any direct or consequential loss arising from reliance on any information presented.